



## MARKSANS PHARMA LIMITED

CIN: L24110MH1992PLC068364

Regd. Office: 11<sup>th</sup> Floor, Grandeur, Veera Desai Extension  
Road, Oshiwara, Andheri (West), Mumbai - 400053.

Phone: 022 4001 2000; Fax: 022 4001 2011

Website: [www.marksanspharma.com](http://www.marksanspharma.com);

E-mail: [companysecretary@marksanspharma.com](mailto:companysecretary@marksanspharma.com)

---

**CORRIGENDUM TO EGM NOTICE**

We draw kind attention of all concerned towards our Notice dated 15<sup>th</sup> June, 2021 calling an Extra-ordinary General Meeting of the Company (**NOTICE**) to be held on Friday, the 9<sup>th</sup> July, 2021 through Video Conferencing/Other Audio Visual Means (VC) at 9.00 a.m. sent through permitted mode on 16<sup>th</sup> June, 2021.

This is with regard to Clause VII of Item No.1 of the Explanatory Statement annexed to the **NOTICE**.

In the table of the said Clause VII of Item No. 1 of the Explanatory Statement in column no. 3, Identity of Ultimate Beneficial Owners of OrbiMed Asia IV Mauritius FVCI Limited is wrongly mentioned as NA. The said table is reproduced hereinbelow with identity of ultimate beneficial owners of OrbiMed Asia IV Mauritius FVCI Limited:

**VII. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/ or who ultimately control the proposed allottees, the percentage of post preferential issue capital that may be held by them:**

Sr. No.	Name & Category of proposed allottee	Identity of Ultimate Beneficial Owners	No. & % of equity shares held prior to the preferential allotment		No. of warrants to be issued and allotted	No. & % of equity share post issue (After exercise of Warrants)*	
			No. of shares	%		No. of shares	%
	<b>Promoter</b>						
1	Mr. Mark Saldanha	NA	17,74,91,553	48.25	10,00,000	19,84,91,553	43.18
	<b>Non-Promoter</b>						
2	OrbiMed Asia IV Mauritius FVCI Limited	1. Sam Block III 2. Ryan Loggie 3. Ashish D. Jagannath 4. Chettensingh Awotarsing 5. Kumaren Appavoo	NIL	NIL	4,93,24,324	4,93,24,324	10.73
<b>Total</b>					<b>5,03,24,324</b>		

*\*Assuming all the Warrants shall be converted into Equity Shares of the Company.*

All concerned are requested to read the above details in the place of Clause VII of Item No. 1 of the Explanatory Statement on page no. 09 of the **NOTICE**.

We regret the inconvenience caused to the Members and all other concerned in this regard.

Kindly note that this Corrigendum to the **NOTICE** is issued by order of the Board to all the Members of the Company and Stock Exchanges as well as others entitled thereto pursuant to section 101 of the Companies Act, 2013. Thus, the **NOTICE** shall always be read with this Corrigendum.

The Corrigendum to the **NOTICE** of the Extra-ordinary General Meeting is being uploaded at the Company's website viz [www.marksanspharma.com](http://www.marksanspharma.com). Please note that e-voting will commence from 9.00 a.m. on Tuesday, July 6, 2021 to 5.00 p.m. on Thursday, July 8, 2021.

**For Marksans Pharma Limited**  
  
**Harshavardhan Panigrahi**  
**Company Secretary**

Date : 30<sup>th</sup> June, 2021  
Place : Mumbai

<div> <div>ALKA INDIA LIMITED</div> <div> CIN: L99999MH1993PLC168521   GST No.: 27AABCA6702F1Z2  Regd. Office: Unit No. 102, 1st Floor, Morja Landmark II, New Link Road, Andheri (W), Mumbai - 400 053.  Tel. No.: 022 - 4972 0369   website: www.alkaindia.in   Email Id: alkaindia@gmail.com </div> </div>						
Statement of Standalone Audited Results for the Year ended 31st March, 2021						
		(₹ In Lakh)				
S. No.	Particulars	Quarter Ended			Year Ended	
		31/03/2021	31/12/2020	31/03/2020	31/03/2021	31/03/2020
		(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from Operations	-	-	-	-	-
II	Other income	(0.00)	-	-	11.02	-
III	<b>Total Income (I+II)</b>	<b>(0.00)</b>	-	-	<b>11.02</b>	-
IV	<b>Expenses</b>	-	-	-	-	-
	Cost of Materials consumed	-	-	-	-	-
	Purchase of stock-in-trade	-	-	-	-	-
	Changes in inventories of finished goods,	-	-	-	-	-
	Stock-in-Trade and Work-in-progress	-	-	-	-	-
	Employee benefits expense	(0.00)	0.30	1.20	1.35	5.34
	Finance costs	-	-	-	-	0.16
	Depreciation and amortisation expense	-	-	-	-	-
	Other expenses	33.36	0.90	3.84	41.46	10.09
	<b>Total Expenses (IV)</b>	<b>33.36</b>	<b>1.20</b>	<b>5.04</b>	<b>42.81</b>	<b>15.59</b>
V	<b>Profit/(Loss) before exceptional items and tax (III-IV)</b>	<b>(33.36)</b>	<b>(1.20)</b>	<b>(5.04)</b>	<b>(31.79)</b>	<b>(15.59)</b>
VI	Exceptional items	-	-	-	-	-
VII	<b>Profit/(Loss) after exceptions items and tax (V-VI)</b>	<b>(33.36)</b>	<b>(1.20)</b>	<b>(5.04)</b>	<b>(31.79)</b>	<b>(15.59)</b>
VIII	Tax expenses:	1.29	-	1.19	1.29	1.19
	(1) Current tax	-	-	-	-	-
	(2) Deferred tax	1.29	-	1.19	1.29	1.19
IX	<b>Profit/(Loss) for the period from continuing operations (VII-VIII)</b>	<b>(34.66)</b>	<b>(1.20)</b>	<b>(6.23)</b>	<b>(33.09)</b>	<b>(16.78)</b>
X	Profit/(Loss) from discontinued operations	-	-	-	-	-
XI	Tax expenses of discontinuing operations	-	-	-	-	-
XII	<b>Net profit/(loss) from discontinued operation after tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit/(loss) for the period (IX+XII)</b>	<b>(34.66)</b>	<b>(1.20)</b>	<b>(6.23)</b>	<b>(33.09)</b>	<b>(16.78)</b>
XIV	<b>Other Comprehensive Income</b>	-	-	-	-	-
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total other comprehensive income net of taxes</b>	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period/year (XIII+XIV)</b>	-	-	-	-	-
	<b>Comprising Profit/(Loss) and Other comprehensive Income for the period</b>	<b>(34.66)</b>	<b>(1.20)</b>	<b>(6.23)</b>	<b>(33.09)</b>	<b>(16.78)</b>
XVI	Paid up Equity Share Capital (face value Rs 1 each, fully paid)	6,343.98	6,343.98	6,343.98	6,343.98	6,343.98
XVII	Earning per equity share of Rs 1/- each	-	-	-	-	-
	(1) Basic	(0.01)	(0.00)	(0.00)	(0.01)	(0.00)
	(1) Diluted	(0.01)	(0.00)	(0.00)	(0.01)	(0.00)

Statement of Consolidated Audited Results for the Year ended 31st March, 2021							(₹ in Lakh)	
S. No.	Particulars	Quarter Ended			Year Ended			
		31/03/2021	31/12/2020	31/03/2020	31/03/2021	31/03/2020		
		(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Audited)		
I	Revenue from Operations	-	-	-	-	-		
II	Other Income	(0.00)	-	0.00	11.02	0.00		
III	<b>Total Income (I+II)</b>	<b>(0.00)</b>	<b>-</b>	<b>0.00</b>	<b>11.02</b>	<b>0.00</b>		
IV	<b>Expenses</b>							
	Changes in inventories of finished goods, Stock-in-Trade and Work-in-progress	-	-	-	-	-		
	Employee benefits expense	-	0.30	1.20	1.35	5.34		
	Finance costs	-	-	-	-	0.16		
	Depreciation and amortisation expense	-	-	-	-	-		
	Other expenses	33.55	0.90	-0.34	41.65	10.36		
	<b>Total Expenses (IV)</b>	<b>33.55</b>	<b>1.20</b>	<b>0.86</b>	<b>43.00</b>	<b>15.86</b>		
V	<b>Profit/(Loss) before exceptional items and tax (III-IV)</b>	<b>(33.55)</b>	<b>(1.20)</b>	<b>(0.86)</b>	<b>(31.98)</b>	<b>(15.85)</b>		
VI	Exceptional items	-	-	-	-	-		
VII	<b>Profit/(Loss) after exceptions items and tax (V-VI)</b>	<b>(33.55)</b>	<b>(1.20)</b>	<b>(0.86)</b>	<b>(31.98)</b>	<b>(15.85)</b>		
VIII	Tax expenses:	1.29	-	1.46	1.29	1.46		
	(1) Current tax	-	-	-	-	-		
	(2) Deferred tax	1.29	-	1.46	1.29	1.46		
IX	<b>Profit (Loss) for the period</b>	<b>(34.84)</b>	<b>(1.20)</b>	<b>(2.32)</b>	<b>(33.27)</b>	<b>(17.31)</b>		
X	<b>Other Comprehensive Income</b>	-	-	-	-	-		
XI	<b>Total Comprehensive Income for the period/year (IX + X)</b>	-	-	-	-	-		
	<b>Comprising Profit (Loss) for the period</b>	<b>(34.84)</b>	<b>(1.20)</b>	<b>(2.32)</b>	<b>(33.27)</b>	<b>(17.31)</b>		
XII	<b>Paid up Equity Share Capital (face value Rs 1 each, fully paid)</b>	<b>6,343.98</b>	<b>6,343.98</b>	<b>6,343.98</b>	<b>6,343.98</b>	<b>6,343.98</b>		
XIII	Earning per equity share of Rs 1/- each							
	(1) Basic	(0.01)	(0.00)	(0.00)	(0.01)	(0.00)		
	(1) Diluted	(0.01)	(0.00)	(0.00)	(0.01)	(0.00)		

**Notes :**

- The Statement of financial result has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and the recognised accounting practices and policies to the extent applicable.
- The above statement of financial results has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30th July 2021.
- The Consolidated results include the financial result of an Indian Subsidiary Vintaze (Pvt) India Private Limited.
- As per the requirements of Ind AS-108, no disclosure is required as the Company is operating in single business segment.
- Demand of Rs 179.51 Lacs includes the interest and penalty under GVAT. The authorities have approved a refund amount of INR 15 lakhs vide Refund Order dated 21st August 2020 and the same was received by the Parent company in its bank account.
- The company name in the list of shell companies (Vide SEBI on its letter bearing no. SEBI/HO/ISD/OWP/2017/18163 dated August 7, 2017). Exchanges had initiated a process of verifying the credentials / fundamentals of the company through exchange. Exchanges had appointed an auditor to conduct audit of the company to verify its credentials/fundamentals. On verification, if Exchanges do not find appropriate credentials / fundamentals about the existence of the company, Exchanges may initiate the proceeding for compulsory delisting against the company, and the said company shall not be permitted to deal in any security on exchange platform and its holding in any depository account shall be frozen till such delisting process is completed. Accordingly, the forensic audit was conducted, however, till date the Parent company has not received any further communication from BSE.
- The Parent Company had received a demand of Rs. 25 Lacs from SEBI vide its order no. EAD/BJD/NJM/R/2017-18 with regards to redressal of investor grievances through SEBI Complaints Redress System (SCORES). The Parent company has filed an appeal against the demand with Securities Appellate Tribunal, Mumbai and vide order dated 7th August 2019, the appeal was dismissed. Later the Parent company contested the same in Supreme Court and vide order dated 24th July 2020, the appeal is dismissed by Supreme Court and the original demand raised by SEBI of Rs. 25 lakhs is upheld. Thus, the Parent company has recognized the liability of Rs. 25 lakhs payable towards the penalty imposed by SEBI on account of non- redressal of investor grievances during the FY 2020-21.
- Previous period's figures have been reclassified, wherever necessary, to correspond with those of the current period.

**For Aika India Limited**  
Sd/-  
**Ashok Pancharyia - Director**  
DIN: 00373931

**Place : Mumbai**  
**Date : 30.05.2021**



केले. मियावाकी वनाबद्दल माहिती देणाना ते म्हणाले की, मियावाकी वनांमध्ये झाडांची नियंत्रित जोपासना करण्यासाठी दोन ते तीन वर्षांचा कालावाची लागतो आणि त्यानंतरही झाडे नैसर्गिक पद्धती वाढतात आणि त्यांची उंची एक वर्षात त्या सुमारे पाच फुटांपर्यंत पोहोचणार. अहो. सर्वसाधारण कालावधीपेक्षा निम्म्या कालावधीत झाडे वाढतात.

मात्रेलेली होती. संबंधीताने  
मालेले अनाधिकृत  
गांधकाम स्वतःहून हटविणे  
आवश्यक होते. परंतु त्यांनी  
सदर ठिकाणी अनाधिकृत  
गांधकाम सुरु ठेवले आहे.

१. कंपनी कायदा, २०१३ च्या अनुच्छेद १३३ अंतर्गत विहित असल्यानुसार त्यांचा अवलंब करण्याकरिता इंडियन अकाउंटिंग स्टॅंडर्ड्स (आयएनडी-एस) यांच्यासह अनुपालनामध्ये तयार केला आहे. सदर पुनःनिर्धारित अहवाल मर्यादित अहवाल यांकरिता नाही.
२. वित्तीय अहवालांचा वरील संपूर्ण निष्कर्ष लेखा समिती द्वारे मंजूर करण्यात आला आहे व दि. ३० जुलै, २०१९ रोजी आयोजित सभेमध्ये मंजूर करण्यात आला आहे.
३. इंडियन ससायझिटी व्हिटेड (एफझेडई) इंडिया प्रायव्हेट लिमिटेड यांच्या वित्तीय अहवालासह स्थायी निष्कर्ष.
४. आयएनडी-एस-१०८ च्या आवश्यकतेनुसार रिंगल बिलीनेस सेगमेंट मध्ये ऑपरिंगिंग अनुसार कंपनी आवश्यक कृत आहे.
५. ₹. १७९.५१ लाखाची मागणी बीबीएलटी अंतर्गत बंद व व्याज यांच्यासह राखिल. प्राधिकरणाने त्यांच्या बँक खात्यामध्ये पॅरेंट कंपनी द्वारे स्विकृत करून दि. २१ ऑगस्ट, २०२० रोजी रिफंड ओव्हर ₹. १५ लाख प्रस्ताव एकम मंजूर केली आहे.
६. कंपनीच्या सूचनांकडे कंपनीचे नाव (सेबी वा त्यांचे पत्र धारक क्र. सेबी/एचआर/१/२०१७/१८१८३ दि. ७ ऑगस्ट, २०१७) अनुसार क्रेडिटेशियल / फंडामेंटल यांची चाचणी करण्याकरिता कंपनीच्या लेखांची निमुकी करण्याकरिता एसबीजे, एसबीजे मार्फत कंपनीचे क्रेडिटेशियल / फंडामेंटल यांची चाचणी प्रक्रिया संचित कृत आहे.
- पडताळणीकरून कंपनीचे योग्य क्रेडिटेशियल / फंडामेंटल सापेक्षत नाही आहेत. बदल कंपनीच्या संबंधात प्रक्रिया करण्याकरिता सूचित करण्यात येतील व सदर कंपनी सेबी रेग्युलेशन यांचे परिचलनातून उत्पन्न बंद करण्याकरिता अतिरिक्त करसमवेत आयएनडी एस सह अनुपालन आवश्यकतेनुसार कंपनीकडे लागू आहेत.
७. सदर कंपनीकडच्या दरम्यान ₹. २५ लाखाच्या सिक्युरिटीड प्रीमियम यांच्यासमवेत सेबी मार्फत इन्वेस्टर चौकशीच्या संबंधात ओव्हरा क्र. ईएडी/बीबीडी/पुनवेसआर/१/२०१७-१८ अंतर्गत सेबी कमलेटर्स रडिस सिस्टम (स्कोअर्स), पॅरेंट कंपनीने दि. ३० ऑगस्ट, २०१९ रोजी ओव्हरा ओव्हरा अंतर्गत सिक्युरिटीड ऑडिट ऑडिट न्यायाकरण, मुंबई यांच्यासह मागणी संबंधात अपील दाखला केला आहे जो अपील दुरु केला आहे. त्यानंतर दि. २४ जुलै, २०२० च्या अंतर्गत सुप्रीम न्यायालयामध्ये सरत आखलेला केला आहे व सेबी द्वारे उडवलेले मूळ मागण्या वा न्यायालय क्र. २५ लाख अपरब्लंड केले आहेत. त्यामुळे वित्तीय वर्ष २०२०-२१ दरम्यान इन्वेस्टर चौकशीच्या गॉन-ट्रिडसलच्या खात्यावर सेबी द्वारे दंडात्मक क्र. २५ लाखाचे दायित्व करण्यात येईल.
८. मागील कालावधीची आकडेवारी सदर कालावधीच्या वार्षिकरण करण्याच्या पुढी करण्याकरिता आवश्यकतेनुसार नव्याने करण्यात येणार आहे / पुनःनिर्धारित करण्यात येत आहे.

**AVAILABILITY OF APPLICATION FORMS:** The Application Forms and copies of the Prospectus may be obtained from the Registered Office of AA PLUS TradeLink Limited, Lead Manager: Venture Merchant Banker Services Private Limited. Application Forms will be available at the selected location of registered brokers, Banker to the Issue, RTA and Depository Participants. Application Forms can also be obtained from the Designated Branches of SCSBs, the list of which is available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in). Application Forms can also be downloaded from the website of Stock Exchange at [www.bseindia.com](http://www.bseindia.com).

**AVAILABILITY OF PROSPECTUS:** Investors should note that investment in Equity Shares involves a high degree of risk and investors are advised to refer to the Prospectus and the Risk Factor contained therein, before applying in the Issue. Full copy of the Prospectus shall be available at the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in); the website of Stock Exchange at [www.bseindia.com](http://www.bseindia.com), the website of Lead Manager at [www.venturemerchantbanker.com](http://www.venturemerchantbanker.com) and the website of the Issuer Company at [www.aaplustradelink.com](http://www.aaplustradelink.com)

**RISK TO INVESTORS:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Prospectus. Specific attention of the investors is invited to the section, "Risk Factors" on page 17 of the Prospectus.

**ADDITIONAL INFORMATION AS REQUIRED UNDER SECTION 30 OF THE COMPANIES ACT, 2013**

**MAIN OBJECTS OF THE COMPANY AS PER MOA:** For information on the main objects and other objects of our Company, see "History and Certain Corporate Matters" on page 73 of the Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection" on page 200 of the Prospectus.

**LIABILITY OF MEMBERS AS PER MOA:** The Liability of the members of the Company is Limited.

**CAPITAL STRUCTURE:** Authorized Capital of ₹ 8,25,00,000 consisting of 82,50,000 Equity Shares of ₹ 10 each. Pre Issue Capital: Issued, Subscribed and Paid-up Capital ₹ 4,56,48,000 consisting of 45,64,800 Equity Shares of ₹ 10 each. Post Issue Capital: Issued, Subscribed and Paid-up Capital ₹ 8,16,48,000 consisting of 81,64,800 Equity Shares of ₹ 10 each. For details of the Capital Structure, please refer to the chapter titled "Capital Structure" beginning on page 40 of the Prospectus.

**NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:** Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: Anagha P Shetty: 24500 Equity Shares; Ashok A. Shah: 25000 Equity Shares; Paresh A Gohil, Hiren M. Parmar, Prakash B. Shetty, Pravin R. Chittoji and Chandu K. Jain: 100 Equity Shares each.

**All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus dated June 30, 2021.**

**Investors should read the Prospectus carefully, including the Risk Factors on page 17 of the Prospectus before making any investment decision.**

**For AA PLUS TRADELINK LIMITED**  
On behalf of the Board of Directors  
Sd/-  
**Ashok A. Shah**  
Managing Director

**Place:** Mumbai  
**Date:** July 1, 2021

**AA Plus Tradelink Limited** is subject to market conditions, public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Mumbai. The Prospectus shall be available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), the website of the Lead Manager at [www.venturemerchantbanker.com](http://www.venturemerchantbanker.com), the website of the BSE i.e. [www.bseindia.com](http://www.bseindia.com), and website of the Issuer Company at [www.aaplustradelink.com](http://www.aaplustradelink.com). Investors should note that investment in Equity Shares involves a high degree of risk. For details investors should refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on page 17 of the Prospectus, which has been filed with ROC.

The Equity Shares have not been and will not be registered under the US Securities Act (the "Securities Act") or any state securities law in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in the Regulations under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act of 1933.